Connor Iapoce

New York

Assistant Editor at HCP Live

Featured in: Favicon

hcplive.com Favicon

contagionlive.com Favicon

newsbreak.com Favicon

ajmc.com

contemporaryobgyn.net Favicon

dermatologytimes.com Favicon

contemporarypediatrics.com Favicon

neurologylive.com Favicon

rheumatologynetwork.com Favicon

tcnjsignal.net + 5 more

Articles

Evolocumab May Shift Plaque Profile Toward Lower Cardiovascular Risk

6 days ago | hcplive.com | Connor Iapoce

Evolocumab may help reshape high-risk plaque in the arteries, with the drug reducing microcalcification activity and shifting plaque toward a lower-risk profile over 18 months in patients with extensive noncalcified plaque at baseline in a new study.1Evolocumab, a human monoclonal antibody targeting PCSK9, was first approved by the US Food and Drug Administration (FDA) in August 2015 to lower low-density lipoprotein cholesterol (LDL-C) in patients needing additional reduction.
MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial

1 week ago | hcplive.com | Connor Iapoce

A novel cholesterol-lowering drug may offer a new approach to reducing cardiovascular risk in patients with elevated triglycerides and remnant cholesterol, beyond the reach of traditional therapies.1 In late-breaking data announced by Marea Therapeutics on May 7, 2025, and presented at the 93rd European Atherosclerosis Society (EAS) Congress, MAR001—a first-in-class monoclonal antibody targeting ANGPTL4—reduced remnant cholesterol and triglycerides by more than 50% compared with placebo at 12...
Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials

1 week ago | consultantlive.com | Connor Iapoce

NewAmsterdam Pharma has announced new Phase 3 data showing once-daily oral obicetrapib, as an adjunct to statins, significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) who do not respond sufficiently to standard therapy.1 Presented as late-breaking research at the European Atherosclerosis Society (EAS) Congress 2025, on May 7, 2025 and simultaneously published in The New England Journal of Medicine and The Lancet, the...
FDA Approves 12.5 mg Chlorthalidone Tablets for Hypertension

1 week ago | hcplive.com | Connor Iapoce

The US Food and Drug Administration (FDA) has approved 12.5 mg chlorthalidone tablets (HemiClor), targeted to lower blood pressure in the treatment of adults with hypertension.1Announced by PRM Pharma, LLC, on May 6, 2025, 12.5 mg chlorthalidone tablets will be available in pharmacies nationwide beginning this month, providing access to a guideline-recommended formulation supported by the American College of Cardiology (ACC) and American Heart Association (AHA).
FDA Accepts NDA Submission for Oral Semaglutide 25 mg

1 week ago | hcplive.com | Connor Iapoce

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) submission for a once-daily 25 mg oral formulation of semaglutide injection (Wegovy) for adults with obesity or overweight.1 Announced by Novo Nordisk on May 2, 2025, the investigational oral formulation of semaglutide is targeted for chronic weight management in patients with obesity or overweight and ≥1 comorbid condition and to reduce the risk of major adverse cardiovascular events (MACE) in those with...
FDA Delays Decision on Elamipretide for Barth Syndrome

2 weeks ago | consultantlive.com | Connor Iapoce

The US Food and Drug Administration (FDA) delayed the target action date for the New Drug Application (NDA) for the investigational medicine, elamipretide, for the treatment of Barth syndrome.1Announced on April 30, 2025, Stealth BioTherapeutics indicated that labelling discussions were initiated with the regulatory agency; however, a revised action date has yet to be communicated for the application for the ultra-rare, life-threatening disease.
Lifitegrast Sustains Rapid Effect for Dry Eye in Real-World Assessment

2 weeks ago | consultantlive.com | Connor Iapoce

A quantitative and qualitative assessment of real-world utilization data reported the rapid and sustained response of lifitegrast ophthalmic solution 5% (Xiidra) for individuals with dry eye disease (DED).1Presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, nearly two-thirds of eye care providers reported near or complete symptom resolution in approximately 1300 patients with DED after 1-3 months of lifitegrast treatment.
Lifitegrast Sustains Rapid Effect for Dry Eye in Real-World Assessment

2 weeks ago | hcplive.com | Connor Iapoce

A quantitative and qualitative assessment of real-world utilization data reported the rapid and sustained response of lifitegrast ophthalmic solution 5% (Xiidra) for individuals with dry eye disease (DED).1Presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, nearly two-thirds of eye care providers reported near or complete symptom resolution in approximately 1300 patients with DED after 1-3 months of lifitegrast treatment.
BRIMOCHOL PF Achieves Durable Near Vision Improvement in Presbyopia

2 weeks ago | hcplive.com | Connor Iapoce

A combination product of preservative-free carbachol 2.75% and brimonidine tartrate 0.1% (BRIMOCHOL PF) achieved durable improvement in functional near vision for patients with presbyopia, with no drug-waning effect over 12 months of dosing in the Phase 3 BRIO-II study.1 Presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, these data showed individuals treated with BRIMOCHOL PF achieved clinically meaningful improvement in near vision and...
Postmarketing Analysis Confirms Safety Profile of Lifitegrast for Dry Eye

2 weeks ago | hcplive.com | Connor Iapoce

A study examining the long-term safety of lifitegrast ophthalmic solution 5% (Xiidra) identified no new or changing signals during routine safety monitoring of patients with dry eye disease (DED) across worldwide postmarketing findings.1 Presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, the cumulative patient exposure, involving 7 years of worldwide postmarketing safety data, was estimated at nearly 800,000 patient treatment years—no new safety...